Evidence map›Paper›PMID 30168749›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2019

gMS-Classifier1 does not predict disability progression in multiple sclerosis.

Johannis A van Rossum, Joep Killestein, Luisa M Villar, Peter N Riskind, Mark S Freedman, Charlotte Teunissen

Open access · hybridAbstract readLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Johannis A van Rossum1 Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-0096-012X
Joep Killestein1 Department of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Luisa M Villar2 Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Peter N Riskind3 Memorial Multiple Sclerosis Center, Department of Neurology, UMass Memorial Medical Center, Worcester, MA, USA.
Mark S Freedman4 Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Charlotte Teunissen5 Department of Clinical Chemistry, Amsterdam University Medical Centers, The Netherlands.
Amsterdam Neuroscience · NLAmsterdam University Medical Centers · NLHospital Universitario Ramón y Cajal · ESUMass Memorial Health Care · USUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionAdolescentAdultAntibodiesBiomarkersFemaleFollow-Up StudiesHumansImmunoglobulin MMaleMiddle AgedMultiple SclerosisPredictive Value of TestsPrognosisYoung AdultAntibodiesBiomarkersImmunoglobulin M

Identifiers

PMID30168749
PMCPMC6545617
OpenAlexW2889534785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.